Dendreon (NASDAQ: [[ticker:DNDN]]), which won FDA approval last week for a new treatment to stimulate the immune system to fight prostate cancer, has found a bigger new home. The company signed a letter of intent to lease a new four-story, 200,000 square foot building on Seattle’s waterfront, according to The Seattle Times. The building, developed by Martin Selig, is at 635 Elliott Avenue. Dendreon spokeswoman Katherine Stueland said the lease is for 15 years, and has two five-year extension clauses. Real estate brokers say this could be one of the biggest local real estate deals of the year, according to The Times.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
